Depression is a common, devastating illness. Current pharmacotherapies help many patients, but high rates of a partial response or no response, and the delayed onset of the effects of antidepressant therapies, leave many patients inadequately treated. However, new insights into the neurobiology of stress and human mood disorders have shed light on mechanisms underlying the vulnerability of individuals to depression and have pointed to novel antidepressants. Environmental events and other risk factors contribute to depression through converging molecular and cellular mechanisms that disrupt neuronal function and morphology, resulting in dysfunction of the circuitry that is essential for mood regulation and cognitive function. Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes that take effect in weeks or months, it has recently been shown that treatment with new agents results in an improvement in mood ratings within hours of dosing patients who are resistant to typical antidepressants. Within a similar time scale, these new agents have also been shown to reverse the synaptic deficits caused by stress.
p e r s p e c t i v e
Depression is a common, devastating illness. Current pharmacotherapies help many patients, but high rates of a partial response or no response, and the delayed onset of the effects of antidepressant therapies, leave many patients inadequately treated. However, new insights into the neurobiology of stress and human mood disorders have shed light on mechanisms underlying the vulnerability of individuals to depression and have pointed to novel antidepressants. Environmental events and other risk factors contribute to depression through converging molecular and cellular mechanisms that disrupt neuronal function and morphology, resulting in dysfunction of the circuitry that is essential for mood regulation and cognitive function. Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes that take effect in weeks or months, it has recently been shown that treatment with new agents results in an improvement in mood ratings within hours of dosing patients who are resistant to typical antidepressants. Within a similar time scale, these new agents have also been shown to reverse the synaptic deficits caused by stress.
Depression is among the leading contributors to the global burden of disease 1 , affecting approximately 17% of the population in the USA. It is associated with enormous personal suffering and societal economic burden 2 . Furthermore, depression can be a lethal illness owing to an elevated risk for suicide 3 , as well as increased risks of cardiac disease, cerebrovascular disorders and other medical causes of mortality 4 . The magnitude of the clinical burden of depression reflects, in part, the limited effectiveness of present-day treatments. Currently available antidepressant medications, alone and in combination, are associated with high rates of partial responsiveness or non-responsiveness, delayed response onset of weeks to months and limited duration of efficacy 5 . Certain approaches, notably electroconvulsive seizure therapy (ECT), have greater efficacy but also have significant side effects, such as retrograde amnesia. The development of truly novel medications that address these limitations has been hampered by a deficient understanding of the pathophysiology of depression. Gaining such understanding is particularly challenging given the clinical heterogeneity of major depressive disorder (MDD), the broad phenomenological criteria used to diagnose depression, and the lack of reliable biomarkers of MDD and treatment response. Despite these complexities, progress is being made.
In this Perspective, we present evidence in support of the hypothesis that depression is caused by disruption of functional and structural connections of the neural circuits that underlie the regulation of mood. We discuss the negative impact of stress-induced physiological changes and (or in combination with) other risk factors on synaptic connectivity of specific neural circuits, and the molecular and cellular mechanisms underlying these effects. Finally, we will consider positive modulators of synaptic connectivity (such as exercise, metabolic balance and the use of anti-inflammatory agents that oppose the effects of these pathophysiological mechanisms, as well as novel, rapidly acting antidepressants.
Risk factors
Susceptibility to depression, as well as to other psychiatric illnesses, is influenced by a variety of genetic, epigenetic, endocrine and environmental risk factors ( Fig. 1 and Boxes 1 and 2). For example, susceptible individuals exposed to traumatic or stressful life events may develop depression; whether they develop disease may be influenced by differences in genetic make-up, exposure to prior stressful experiences and other physiological parameters (for example, gonadal hormone levels and metabolic imbalances). Conversely, some factors increase resilience and boost the ability to avoid the damaging effects of traumatic or chronic stress 6 . Resilience to depression can be the result of the absence of negative responses observed in susceptible individuals or of the adaptive mechanisms that promote normal mood and emotion. Inter-individual susceptibility factors can also explain the heterogeneity of depression. Abnormal abundance or function of the hypothalamic-pituitary-adrenal (HPA) axis, neurotrophic factors, sex steroids, and metabolic and/or inflammatory cytokines can lead to alterations in neurotransmitters, intracellular signaling, gene transcription, translation and epigenetic changes that can contribute to short-term and long-lasting imbalances of neuronal function and behavior.
Depression: disruption of synapse number and function Disruption of complex mood-related circuitry has been implicated in depression (Box 3), but among the findings of altered brain structure and function in depression, the most consistent finding is the reduced volume of the prefrontal cortex (PFC) and hippocampus 7, 8 . The extent of volume reduction is correlated with length of illness and time of treatment, and with the severity of depression. Recent post-mortem studies also demonstrate reduced synapse number in the PFC of subjects with depression 9 . Studies in rodent models have extended these human studies and confirm that, like depression, exposure to stress causes atrophy and the loss of neurons and glia in the PFC and hippocampus [10] [11] [12] (Fig. 2) .
Synaptic plasticity represents one of the most fundamental and important functions of the brain-the ability to sense, assess and store complex information, and to make appropriate, adaptive responses to subsequent related stimuli [13] [14] [15] . This critical brain function has a key role in both short-and long-term memory, and the mechanisms underlying these changes have been linked to the pathophysiology and treatment of multiple neurobiological disorders, including depression.
Synaptogenesis is regulated by a complex interaction of signaling pathways, and disruption of many of the key pathways have been implicated in the susceptibility to depression-including loss of neurotrophic factor support, disruption of estradiol cycling and elevation of inflammatory cytokines 10 (Fig. 3) . Glia also have an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology 16, 17 . Here we discuss the major systems implicated in the susceptibility and pathophysiology of depression, and how they influence synaptic connections in depression circuitry.
Stress and depression: HPA axis and glucocorticoids
The most significant susceptibility factor for depression is acute traumatic or chronic stress. Exposure to stress could occur during early life, causing long-lasting alterations (such as epigenetic alterations of DNA and/or histones; see Box 2) that contribute to abnormal behavior, or it could occur in adulthood [18] [19] [20] . A hallmark feature of the stress response is the activation of the HPA axis and increased levels of circulating glucocorticoids, which is designed to provide maximum physiological support in the acute phase of the 'fight-or-flight' response. However, repeated exposure to stress and sustained elevation of glucocorticoids has deleterious effects on multiple organ systems, including the brain. Depression is often associated with elevated HPA axis activity and increased levels of glucocorticoids, as well as disruption of negative-feedback mechanisms [21] [22] [23] .
Elevated concentrations of glucocorticoids function at multiple levels to influence neuronal function and behavior. Notably, chronic exposure of rodents to adrenal glucocorticoids decreases synaptic number and function and causes atrophy of neurons in the PFC and hippocampus, regions undergoing atrophy and disruption of connectivity in individuals with depression 24, 25 . Acute stress also increases levels of extracellular glutamate in rodents, suggesting that excitotoxicity could contribute to neuronal atrophy 26, 27 . Recent studies in rodents and humans also demonstrate a role for glucocorticoid regulation of molecular signaling pathways that influence gene transcription via epigenetic mechanisms, including that involving the regulation of the glucocorticoid receptor itself 28 . Variations of genes in the HPA Figure 1 Heterogeneity of depression and influences on susceptibility to depression. The heterogeneity of depression results from one or more pathological determinants. Notable influences include stress on brain neurotransmitter systems, activation of the HPA axis and cortisol, the innate immune system and inflammatory cytokines, fluctuations of ovarian steroids, the gastrointestinal (GI) system, adipose tissue and related peptides, the microbiome, the cardiovascular system (for example, vascular endothelial growth factor (VEGF)), and gene polymorphisms that influence vulnerability and other organ systems as shown. These systems lead to an increased incidence of depression, as well as to comorbid illnesses.
Box 1 Hereditary patterns of depression and gene-by-environment interactions
Genetic vulnerability accounts for ~35-40% of the variance in depression 179 . Early genetic studies focused on treatment-related candidate genes (such as those encoding monoamine receptors and transporters), but these were underpowered and/or have not been replicated 29, 180 . More recent genome-wide association studies (GWAS), which have been successful in identifying gene loci involved in schizophrenia, have not yet yielded replicable findings for MDD. This is thought to be due to the small number of MDD cases in reported studies relative to the 75,000-100,000 cases estimated to be required to generate replicable findings that are statistically significant 181 . The large sample sizes needed for these studies may be because of clinical heterogeneity, modest heritability (~40%) and the complexity of the genetic architecture for depression, i.e., a large number of interacting loci with small effect sizes 181 . Nonetheless, a recent GWAS pathway analysis of over 60,000 cases found significant associations between immune, neuronal signaling, synaptic density and histone cascades and psychiatric disorders, including MDD, suggesting a clustering of risk variants in these pathways 182 .
With the accumulating number of clinical samples, next-generation sequencing may identify rare single-nucleotide variants or rare copynumber variants that contribute to the genetic risk for MDD 29 . Interactions of genetic vulnerability with environmental susceptibility factors most probably contribute to the complexity and heterogeneity of depression. These studies have focused primarily on early-life stress or trauma, but gene-by-environment interaction studies are being expanded to include protective factors such as social support and intervention, as well as genes that increase resilience to depression 29, 183 . p e r s p e c t i v e axis, including those encoding corticotropin-releasing hormone (CRH; also known as CRF) receptor 1 (CRHR1) and FK506-binding protein 5 (FKBP5), have been suggested to have a functional interaction with stressful life events and/or childhood abuse and/or trauma, although further studies are needed to confirm these effects 29 . In addition to disruption of neurotrophic factor signaling (see below), there is new evidence from rodent and human studies that stress and glucocorticoids directly influence the expression of factors that negatively regulate the translation of synaptic proteins (Fig. 3 ) 30 .
The adaptive, evolutionary significance of disrupted synaptic plasticity in response to stress is not clear. One hypothesis is that extrasynaptic NMDA receptors function as neural sensors for metabolic or oxidative stress, causing regression of dendritic spines and branches that protects neuronal viability 17, 31 . However, it is possible that these adaptive changes also have functions that are not yet well understood at the neural-network and whole-animal level and which may be related to a coordinated organismal stress response. Thus, it is likely that chronic stress, combined with genetic and environmental factors, results in short-term adaptive changes (such as mobilization of glucose and activation of immunity) that may have deleterious long-term consequences for synapses, the brain as a whole, and the overall health and viability of the animal (i.e., multiple other stress-related medical disorders). Furthermore, transgenerational epigenetic transmission may help to prepare newborns to cope in specific ways with adverse environments to which the parent had been exposed. As is the case with many stressrelated disorders, such as post-traumatic stress disorder, the longstanding epigenetic adaptations to extremes become dysfunctional after the organism returns to a more congenial environment.
Box 2 Epigenetics and depression
Stress and environmental factors influence neuronal function and behavior through a variety of mechanisms, including acute signaling pathways that transiently regulate cell function. However, alterations may also be persistent and contribute to the life-long stress sensitivity following early-life stress. One of the best-studied mechanisms for persistent changes in gene expression is through epigenetic alterations that influence chromatin structure and gene transcriptional activity 19, 184 . Chromatin structure is determined by histone modifications (such as acetylation) that relax the spacing between nucleosomes and thereby activate gene transcription or by histone methylation that decreases activity. DNA can also be modified, notably via methylation that typically causes transcriptional repression. Studies in rodent models and in human subjects with depression, using both brain tissue and blood cells, have reported epigenetic alterations, including histone and DNA modifications, caused by stress and associated with depressive behaviors 19, 184 . The potential significance of these epigenetic alterations is supported by studies demonstrating that treatment with histone deacetylase inhibitors produce antidepressant responses in rodent models 19, 184 . In addition to alterations in the brain, epigenetic modifications to germ cells may constitute a novel heritable form of neuro-adaptation to stress 185 .
Box 3 Neurocircuitry of depression
Regions within the orbital PFC (oPFC) and the mPFC appear to work as a coordinated unit to integrate sensory information, provide emotional salience and modulate visceral motor reactions and value-based decision processes 186 . The oPFC and ventral lateral PFC, along with the dorsal anterior cingulate (dACC), are positioned at the interface of multimodal sensory networks that mediate emotion and memory. These regions have connections with several sensory areas 187 , as well as inputs from the hypothalamus, amygdala, nucleus accumbens and hippocampus. Neurons in this region are capable of integrating multimodal stimuli with rewarding or aversive qualities 188, 189 . The mPFC and the closely associated pre-genual and subgenual ACC are primarily considered to be modulators of emotion-driven visceral reactions. The mPFC and the pre-genual and subgenual ACC regions have multiple outputs to other cortical regions, as well as to the hypothalamus, periaqueductal gray, locus coeruleus and autonomic nuclei within the brain stem, allowing for modulation of vegetative and visceral functions 190, 191 . In rodents, the infralimbic PFC (IL-PFC) is believed to have roles similar to those of the oPFC-mPFC networks, by integrating information and modulating visceral reactions that are related to emotional processes through connections with the amygdala, hypothalamus and various brain stem nuclei 192 . Recent work suggests that the IL-PFC also modulates activation of the ventral tegmental area through effects on the amygdala and ventral subiculum, tying the region to subcortical reward-processing networks 193 .
Disruption of the mPFC-oPFC networks and altered functional connectivity of the circuits in which they are contained has been tied to the changes in implicit emotional regulation and reward responsiveness, which are core components of depression 194 . Multiple studies have provided evidence of reduced functional connectivity between the amygdala and the mPFC and associated ACC regions. Other studies suggest elevated resting-state activity in these regions and an enhanced amygdala response to emotional stimuli, especially to negative valance stimuli (sadness or fear) in patients with mood disorders. These same brain regions are key components in a 'defaultmode node network', a functionally interconnected set of networks that are active at 'rest' but which are relatively silenced by tasks requiring attention to external stimuli. Increased default-mode network activity is associated with an introspective state, and a reduced ability to modulate the network's activity may impair an individual's ability to shift attention from introspective processes to tasks that require attention to external stimuli.
Anhedonia, especially deficits in non-consummatory reward behavior, is another core symptom of depression. Abnormal activity levels in the PFC-ACC, as well as in the ventral and dorsal striatum, have been reported in depressed patients with anhedonia 195 . Ventral striatal dysfunctions are hypothesized to reflect faulty coding of motivational significance and an impaired ability to accurately update predictions about an expected reward on the basis of previous experiences, whereas impairments within dorsal striatal regions are believed to be more closely tied to defective action-reward contingency learning. Finally, abnormal function of the mPFC-oPFC and ACC regions and their connections to the striatum have been associated with deficits in reward-learning and effort valuation and in an impaired ability to generate adaptive responses to changes in environmental stimuli. Reduced neurotrophic factor expression in stress and depression Neurotrophic (growth) factors-most notably brain-derived neurotrophic factor (BDNF), but also vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2) and insulin-like growth factor 1 (IGF1)-have been implicated in having a role in depression. Stress and depression decrease the expression and function of BDNF ( Fig. 2) in the PFC and hippocampus, structures that are implicated in depression, as well as decrease the BDNF levels in the blood of subjects with depression 21, [32] [33] [34] [35] . Conversely, typical antidepressant treatments (such as selective serotonin-reuptake inhibitors (SSRIs)) increase BDNF expression and block the deficits in growth factor expression caused by stress and depression. Reduced neurotrophic or growth factor levels may be particularly relevant to the structural alterations caused by stress and depression, as these factors (particularly BDNF) are required for activity-dependent formation and maintenance of synaptic connections 13, 36 . Studies of a human BDNF polymorphism (BDNF Val66Met ) that is found in approximately 25% of the population have been insightful. The presence of the BDNF Val66Met allele, whose product results in a block to the processing and release of mature BDNF, is sufficient to cause atrophy of neurons in the hippocampus 37 and medial PFC (mPFC) of mice with this allele 38 . Heterozygous deletion of BDNF also decreases spine density and dendrite length of hippocampal and PFC neurons, decreases hippocampal volume and occludes the effects of chronic stress 39, 40 . These findings suggest that stress could cause neuronal atrophy via inhibition of BDNF or that BDNF is required for neuronal remodeling. Studies with mutant mice have also demonstrated that Bdnf is required for the behavioral actions of antidepressants and that its Figure 2 Chronic stress causes atrophy of neuronal processes and decreases synapse number. (a) The influence of repeated-restraint stress (7 d) on pyramidal neurons (layer V) in the mPFC of rat 24 . Pyramidal neurons in sections of mPFC are visualized after filling the cells with neurobiotin and using two-photon laser-scanning microscopy. The left-hand set of images shows that stress induces a reduction in the number and length of apical dendrites. The right-hand set of images shows a magnified segment of dendrite, with its spines at the point of synaptic contacts with neuronal inputs to the mPFC; repeated stress significantly decreases the number and function (determined using electrophysiology; data not shown) of spine synapses. (b) Under normal conditions stimulation of the presynaptic neuron releases glutamate, resulting in the activation of postsynaptic glutamate AMPA receptors and depolarization; this causes activation of multiple intracellular pathways, including the BDNF-TrkB signaling pathway (and the downstream kinases Akt and ERK) and the mTORC1 pathway. These pathways are essential for regulation of synaptic plasticity, a fundamental adaptive learning mechanism that includes maturation (increased spine-head diameter) and an increase in the number of synapses. This process requires mTORC1-mediated de novo protein synthesis of synaptic proteins, including glutamate GluA1 AMPA receptors and PSD95. Repeated stress decreases BDNF and mTORC1 signaling in part via upregulation of the negative regulator REDD1 (regulated in DNA damage and repair), which decreases the synthesis of synaptic proteins and thereby contributes to a decreased number of spine synapses. Other proteins that are involved in the regulation of synaptic plasticity include GSK3 and protein phosphatase 1 (PP1).
deletion increases vulnerability to depression 41, 42 . In humans, individuals with the BDNF Val66Met allele have reduced episodic memory and executive function, as well as reduced hippocampal volume. In addition, carriers of the BDNF Val66Met allele are at increased risk for depression after exposure to early-life stress or trauma [43] [44] [45] .
The intracellular signaling pathways that mediate the actions of neurotrophic factors on synaptic connections, as well as on neuronal survival and function, include pathways that are involved in tyrosine kinase receptor activation for phosphatidylinositide 3-kinase (PI3K)-protein kinase B (also called Akt) and the mitogen-activated protein (MAP) kinases Raf, MEK and ERK [46] [47] [48] (Fig. 3) . These pathways have been linked to multiple downstream targets that influence many aspects of neuronal function, including the protection and survival of neurons and the induction of synaptic plasticity. A key downstream convergence pathway for activity-dependent synaptic plasticity and translation of synaptic proteins is the mechanistic target of rapamycin complex 1 (mTORC1) 46, 49 . The mTORC1 pathway is regulated by neurotrophic-factor signaling but also by endocrine, metabolic, nutritional and energy status, and it could therefore provide a nexus for multiple susceptibility factors (Fig. 3) 49 .
In this way, mTORC1 serves as a neuronal sensor of activitydependent demand for new protein synthesis and synaptogenesis, which is balanced against the metabolic health of the neuron and organism. It is notable that the expression and function of mTORC1 signaling proteins is reduced in post-mortem PFC samples from subjects with depression, which could contribute to decreased synthesis of synaptic proteins in PFC tissue from individuals with depression 50, 51 . 
Conversely, rapid-acting antidepressants (discussed below) stimulate mTORC1 signaling in the PFC 52, 53 . Post-mortem studies demonstrated that the expression of REDD1 (encoded by DNA damage-inducible transcript 4 (DDIT4) in humans), a negative regulator of mTORC1, is increased in the PFC of subjects with depression 30 . Rodent studies also demonstrated that chronic stress decreases mTORC1 signaling proteins 30, 54, 55 , that overexpression of Ddit4 causes loss of synapses in the PFC and that Ddit4 −/− mice are resilient to the synaptic and behavioral deficits caused by chronic stress 30 , further implicating mTORC1 signaling in stress, depression and antidepressant responses.
Sex differences in susceptibility to depression
Depression is approximately twice as common in women than in men 2 , and fluctuations of gonadal steroids (i.e., estrogen and progesterone) associated with the reproductive life cycle (puberty, menstrual cycle, childbirth and menopause) contribute to depression vulnerability 56, 57 . Mood and/or symptoms of depression in these disorders are associated with a precipitous drop in estradiol 58 , and sex steroids affect many aspects of neuronal function that may contribute to the risk for depression [58] [59] [60] .
Estrogen influences neurotransmitter activity, neurogenesis and neurotrophic factor expression, as well as many aspects of glial function 58, 61, 62 . Notably, BDNF levels fluctuate with the estrous cycle, and estrogen administration can increase the expression of Bdnf in the PFC and hippocampus [63] [64] [65] [66] . Dendrite complexity and spine synapse density also fluctuate with the ovarian cycle, and estrogen administration increases spine density in the hippocampus and PFC [67] [68] [69] . Estrogen and increased spine density are also associated with improvements in learning and memory in rodent models [70] [71] [72] . The BDNF Val66Met polymorphism interacts with estrogen and the estrous cycle, resulting in disruption of memory and signaling 73 . Estrogen administration also has antidepressant actions in rodent behavioral models, and there has been clinical evidence of estrogen's antidepressant effects in humans, although there have also been negative reports 57, 59 . Estrogen Figure 3 The multiple heterogeneous signaling pathways that influence synapse formation and stability and that could contribute to loss of synapses in depression. Pathways that affect synapse formation include neurotransmitters (e.g., glutamate), growth factors and neurotrophic factors (GFs/NTFs), cytokines (e.g., TNF-α), energy and metabolic factors (e.g., ATP and amino acids), sex steroids (e.g., estrogen) and the HPA axis (the glucocorticoid cortisol). These influence multiple intracellular signaling cascades that regulate all aspects of neuronal function. One of the key pathways of interest is the mTORC1 signaling cascade, which is a sensor for synaptic activity and systems that can influence synaptic protein synthesis as shown. Activation of mTORC1 signaling can occur via regulation of PI3K and stimulation of Akt. PI3K can be directly or indirectly (via multiple steps) stimulated by the different factors indicated, notably glutamate (via AMPA or mGlu receptors (mGluRs)), estrogen (via estrogen receptors (ER)), BDNF, and other neurotrophins and growth factors. By using the glucocorticoid receptor (GR), stress and glucocorticoids can inhibit mTORC1 signaling by inducing factors that inhibit mTORC1 stability. Metabolic factors (including ATP and amino acids) that are required for protein synthesis can also regulate mTORC1. Activation of mTORC1 signaling leads to increased synthesis of proteins (such as GluA1 and postsynaptic density protein 95 (PSD95)) required for the maturation of existing synapses and the formation of new ones. The insertion of GluA1 is also a point of regulation, notably by GSK3, and is involved in cellular models of learning and memory (i.e., long-term potentiation (LTP) and long-term depression (LTD)). Raptor, regulatory-associated protein of mTOR; Pras40, proline-rich Akt substrate. also blocks neuronal atrophy caused by stress and glucocorticoids 72 , consistent with the hypothesis that disruption of estrogen signaling could result in synaptic deficits and depression-like behaviors. In addition to the well-characterized nuclear estrogen receptors (ERs) that regulate transcription, estrogen acts rapidly on several pathways-including the PI3K-Akt and MAPK-ERK pathways and mTORC1 signaling-that are regulated by growth factors and that could contribute to the neuroprotective and synaptic effects of estrogen 59, 74, 75 (Fig. 3) . These pathways have also been linked with estrogen-induced enhancement of memory in rodent models and in human studies 58, 59, 76, 77 . In addition to regulation of these signaling pathways, regulation of the serotonin system could contribute to the synaptic and antidepressant actions of estrogen 59 . Together, these findings demonstrate molecular mechanisms through which fluctuations in gonadal steroid levels, particularly decreases in estrogen, may contribute to the increased incidence of depression in women.
Metabolic imbalance and diabetes: peptides and related signaling pathways
Metabolic disorders, such as obesity and diabetes, are associated with elevated rates of depression and share risk factors such as social and traumatic stress [78] [79] [80] [81] [82] [83] (Fig. 4) . Elevated amounts of glucocorticoids and inflammatory cytokines are associated with obesity, as well as depression [84] [85] [86] . Obesity and diabetes are also associated with disruption of PFC circuits and neurotransmitter systems (such as those involving serotonin, dopamine, endocannabinoids and opioids) involved in motivation, reward and anxiety that overlap with depression circuits 80, [87] [88] [89] . Circulating peptides, including leptin and adiponectin from adipose tissue and ghrelin from stomach, that influence feeding behavior and/or energy homeostasis 90 are also regulated by stress and influence depression and anxiety behavior in rodent models [91] [92] [93] [94] . Feeding, energy homeostasis, endocrine and neurocrine systems are also influenced by the gut microbiome, which has been implicated in healthy behavior, whereas an imbalanced microbiome-brain interacnpg p e r s p e c t i v e nature medicine VOLUME 22 | NUMBER 3 | MARCH 2016 Figure 4 Mechanism of action of the fast-acting antidepressant ketamine in the mPFC. Ketamine causes a burst of glutamate that is thought to occur via disinhibition of GABA interneurons; the tonic firing of these GABA interneurons is driven by NMDA receptors, and the active, open-channel state allows ketamine to enter and block channel activity. The resulting glutamate burst stimulates AMPA receptors, which causes depolarization and activation of voltage-dependent Ca 2+ channels (VDCC), leading to release of BDNF and stimulation of TrkB and Akt, which then activates mTORC1 signaling, leading to the increased synthesis of proteins that are required for synapse maturation and formation (i.e., GluA1 and PSD95). Under conditions in which BDNF release is blocked (such as in knockin mice with the BDNF Val66Met allele) or neutralized (using a neutralizing antibody), or in which mTORC1 signaling is blocked (such as rapamycin infusion into the mPFC), the synaptic and behavioral actions of ketamine are blocked. Scopolamine also causes a glutamate burst via blockade of acetylcholine muscarinic M 1 (ACh-M 1 ) receptors on GABA interneurons. Antagonists of mGluR2/3 also produce rapid antidepressant actions via blockade of presynaptic autoreceptors that inhibit the release of glutamate. Relapse to a depressive state is associated with a decrease of synapses on mPFC neurons, which could occur via stress and imbalance of endocrine hormones (cortisol), estrogen, inflammatory cytokines, and metabolic and cardiovascular illnesses.
tion has been linked to psychiatric illnesses, including depression and anxiety [95] [96] [97] . Stress and immune or inflammatory systems can also interact with the gut microbiome and contribute to psychiatric, as well as metabolic, diseases. However, it should be pointed out that the data linking diabetes, obesity and depression are correlative and that further studies are needed to identify direct functional evidence linking these disorders. Dysfunction of energy metabolism and cellular respiration are also associated with depression, as well as with obesity and diabetes. Abnormalities of mitochondrial energetics have been reported in mood disorders, including depression and bipolar disorder, as well as in obesity 80, [98] [99] [100] . Further evidence of metabolic dysregulation is provided by studies demonstrating that impaired peripheral glucose regulation is associated with cognitive decline and depression, especially in obese subjects and in individuals with type 2 diabetes 101 . Consumption of a high-fat diet (HFD) leads to a metabolic syndrome, insulin resistance and type 2 diabetes, conditions that are associated with cognitive deficits and neurodegenerative disorders 102, 103 . A HFD can also lead to anxiety and depressive behaviors in rodent models that are associated with disruption of neurotransmitter circuit connections 103, 104 .
One of the consequences of insulin resistance is altered neuronal function, as a result of either disrupted energy metabolism or loss of insulin actions on neuronal function. HFD-induced, or experimental, diabetes and insulin resistance cause neuronal atrophy in cortical and limbic structures and are associated with reduced synaptic plasticity [104] [105] [106] . BDNF also has a central role in energy metabolism and cellular respiration [107] [108] [109] , and it exerts significant control over feeding behavior and body mass 110 .
There are multiple interactions of signaling pathways for metabolic factors, energy metabolism, and stress/depression systems, notably the growth factor signaling pathways (Fig. 3) . Consumption of a HFD causes insulin resistance in cortical and limbic structures, including decreased insulin-dependent stimulation of Akt, S6 kinase (S6K), glycogen synthase kinase (GSK)-3β and mTORC1 signaling, whereas AMP-activated protein kinase (AMPK) stimulation is increased 104 . These pathways also mediate the actions of growth factors and are disrupted by reductions in BDNF that are caused by diet and stress 80 . Energy metabolism also regulates AMPK, another nodal regulator of mTORC1 signaling and synaptic protein synthesis. The possibility that insulin resistance and disruption of these signaling pathways could contribute to psychiatric illnesses is provided by studies of mice with brain-specific deletions of insulin receptors; these mice are characterized by a disruption of mitochondrial function and an imbalance of brain monoamine metabolism, which are associated with increased anxiety and depression-like behaviors 111 .
These findings suggest that the high rates of comorbidity between depression, diabetes and obesity in the developed world result in part from insulin resistance, abnormal energy metabolism and nutrient delivery to the brain-processes that are exacerbated by the damaging effects of adrenal glucocorticoids and inflammatory cytokines. In contrast, exercise produces dramatic beneficial effects, including the increased expression of BDNF, mTORC1 signaling and muscle-derived factors that increase neural plasticity and resistance to chronic stress exposure 49, 112, 113 .
Innate immune system, the inflammasome and inflammatory cytokines Psychological and social stressors can increase levels of inflammatory cytokines in humans, and cytokine infusions (for example, interferon) can produce sickness behavior with characteristics of depression [114] [115] [116] [117] . Serum levels of the pro-inflammatory cytokines interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α are increased in depressed patients, and cytokine levels are normalized by antidepressant treatment 118, 119 . Recent studies demonstrate a role for inflammasome activation in the effects of stress 115, 120, 121 .
Inflammatory cytokines derived from microglia, the brain's resident innate immune cells, influence synaptic plasticity and spine synapse formation at physiological conditions [122] [123] [124] [125] [126] . Notably, low levels of TNF-α and IL-1β support synaptic plasticity via regulation of PI3K-Akt signaling. However, stress, aging and inflammation induce abnormal elevations of inflammatory cytokines that have the opposite effect via regulation of the signaling factors p38 and NF-κB, which are involved in canonical cytokine signaling pathways. Microglia are [127] [128] [129] and may be recruited during exposure to stress to participate in activity-dependent synaptic loss. Together these studies demonstrate that normal brain function requires low levels of inflammatory cytokines but that elevated levels contribute to damage, atrophy and loss of spine synapses in response to stress and depression.
A role for inflammatory cytokines in the pathophysiology and treatment of depression in humans is supported by recent studies demonstrating that neutralization of TNF-α in patients with psoriasis also reduces symptoms of depression 130 . A second study supports and extends these findings, demonstrating that only patients with elevated C-reactive protein, an inflammation biomarker, show an antidepressant response to the TNF-α antagonist infliximab 131 . Also of note is evidence that patients with normal cytokine levels have worsened symptoms of depression after TNF-α neutralization, consistent with the notion that cytokines are needed for normal brain function.
Antidepressants and synaptic plasticity Chronic administration of typical antidepressants that block the reuptake and breakdown of monoamines increase synaptic plasticity at several levels-including increased birth of new neurons in the adult hippocampus, increased neurotrophic factor expression and regulation of synapse formation 10, 132, 133 . Stress-induced deficits of adult hippocampal neurogenesis have been implicated in the cognitive deficits associated with stress and depression, and these are reversed by antidepressant treatments 134 . Different classes of antidepressants-including SSRIs, dual-and triple-reuptake inhibitors, dopaminergic agents, tricyclics and ECT-increase BDNF expression, and the behavioral actions of these agents are blocked in Bdnf −/− mice [135] [136] [137] [138] . In particular, ECT causes a large induction of BDNF expression in the hippocampus and PFC that could be related to the greater therapeutic efficacy of this treatment, as compared to those with typical antidepressants (such as SSRIs); ECT is still considered the gold standard for difficult-to-treat depression. The ability of ECT to enhance synaptic plasticity, including increased connectivity and even structural alterations, has been directly linked to the greater therapeutic response to this treatment 139, 140 .
In addition to studies using ECT, the consequences of increased BDNF expression on synaptic plasticity after treatment with typical antidepressants have been examined, particularly for the SSRI fluoxetine. Chronic administration of fluoxetine increases synaptic plasticity in cellular models and enhances plasticity in ocular-dominance fields and extinction-of-fear conditioning in adult animals, effects that are dependent on BDNF [141] [142] [143] . There is also evidence, although limited, that chronic administration of a typical antidepressant can increase spine density 144 or block the effects of chronic stress 145, 146 .
However, the therapeutic limitations of these pharmacological agents-notably the substantial time lag, low rates of efficacy and side effects-highlight major unmet needs ( Table 1) . These limitations may be owing to the targeting of monoamine neurotransmitters that predominately serve a modulator role and do not substantially influence synaptopgenesis. With regard to BDNF, treatment with typical antidepressants only increases the expression of BDNF; however, activitydependent synapse formation and plasticity require BDNF release into the synapse in combination with activation of other cellular pathways that contribute to plasticity 21, 33, 47, 147 . The induction of BDNF expression by typical antidepressants, which still requires weeks of drug administration, only produces subtle alterations of BDNF release and function that seem to be inadequate for the level of synaptic plasticity required to alleviate depressive symptoms. ECT produces a rapid, synaptic activity-dependent induction of BDNF in rodents, although it still requires several weeks of treatment to produce a therapeutic response; this delay could be related to the intensity and broad depolarizing effects on the entire brain that could lead to activation of negative-feedback pathways that oppose the neurotrophic actions of ECT (for example, effects that could contribute to retrograde amnesia).
The discovery of agents that possess rapid-acting antidepressant properties is changing our understanding of antidepressant treatment. A single, intravenous or intranasal sub-anesthetic dose of ketamine, a non-competitive NMDA glutamate receptor channel blocker, produces a rapid onset of antidepressant response that can last several days in the majority of individuals with treatment-resistant unipolar and bipolar depression who are participating in a growing number of clinical trials [148] [149] [150] . Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants that have low efficacy and delayed onset of action 151, 152 . In addition to ketamine, there is evidence that low doses of scopolamine, a nonselective cholinergic muscarinic receptor antagonist, also produce rapid antidepressant actions in subjects with depression, providing early evidence for a class of rapid-acting agent different from that of ketamine 153 . This raises the possibility that the anticholinergic actions of tricyclic reuptake inhibitors could contribute to the therapeutic actions of these agents. The rapid antidepressant and antisuicide actions of ketamine and scopolamine, by mechanisms completely different from those of typical monoamine reuptake inhibitors, represent a significant discovery for the treatment of mood disorders. Additional large-scale clinical studies are needed to further substantiate the clinical efficacy of ketamine and scopolamine in different populations of individuals with depression 154, 155 .
Rapid acting antidepressants: mechanism of action Clinical reports of rapid antidepressant actions have led to basic research studies for ketamine and scopolamine, but the molecular and cellular mechanisms underlying the rapid and efficacious actions of these agents are more complicated than simple NMDA-and muscarinic-receptor blockade. Rapid responses in subjects with treatment-resistant depression suggest a mechanism that results in fast changes in synaptic function and plasticity. In contrast to the effects of stress, ketamine and other NMDA receptor antagonists increase mTORC1 signaling via activation of Akt and ERK, and increase synaptic number and function in the PFC 52, [156] [157] [158] (Fig. 4) . This leads to increased synthesis of synaptic proteins that are required for synapse formation and maturation, effects that are blocked by preadministration of the selective mTORC1 inhibitor rapamycin 52, 156, 159 . It is notable that the acute dissociative effects of ketamine subside within ~1 h, whereas the synaptic changes persist for a week or more and that these long-lasting structural changes correlate with its persistent antidepressant behavioral effects. Ketamine's acute activation of both mTORC1 and dendritic mRNA translation of synaptic proteins can be seen as a trigger for the subsequent persistent synaptogenic and behavioral actions of ketamine.
The mechanisms by which an NMDA receptor antagonist leads to induction of mTORC1 and synaptogenesis occur through indirect pathways. Ketamine-mediated induction of mTORC1 signaling and antidepressant behavior is dependent on glutamate transmission and AMPA receptor activation 52, 160 . There is evidence that NMDA receptor blockade increases glutamate transmission in rodents and humans via blockade of NMDA receptors on GABAergic npg p e r s p e c t i v e nature medicine VOLUME 22 | NUMBER 3 | MARCH 2016
interneurons 27, 161, 162 . There is also evidence that AMPA receptor activation stimulates mTORC1 signaling in cultured neurons via the release of BDNF and the activation of Akt and ERK signaling 36, 163 . This possibility is supported by recent reports that ketamine-mediated induction of antidepressant behavioral responses are blocked in Bdnf-null mice 164, 165 .
The rapid induction of mTORC1 signaling and synaptogenesis could serve to reverse the loss of connections in individuals with depression and thereby reinstate the function of PFC and appropriate inhibitory control of the amygdala and emotion. This possibility is supported by studies in a rodent chronic-stress model of depression-in which exposure to stress for several weeks causes atrophy of PFC neurons and anhedonia, a hallmark feature of depression 55 . These morphological and behavioral deficits are rapidly reversed by a single dose of ketamine.
Together, these studies demonstrate that NMDA receptor antagonists rapidly increase mTORC1 signaling and synaptogenesis and reverse the deficits caused by stress and depression. Brainimaging studies support this possibility, demonstrating that ketamine increases connectivity between the PFC and other limbic structures in individuals with depression 166, 167 .
In contrast to the actions of NMDA antagonists, acute or chronic administration of typical antidepressants (such as SSRIs) does not increase mTORC1 signaling 52 . These findings suggest that alteration of mTORC1 signaling and synaptogenesis is important in the rapid and efficacious treatment of depression.
Novel targets for rapid-acting antidepressants
If the rapid onset of antidepressant actions of ketamine can be confirmed by future clinical trials, then it will represent a major advance for the treatment of mood disorders. However, the potential for abuse and the neurotoxicity associated with high, repeated dosing pose challenges to its broader use in clinical settings and highlight the need for safer drugs that produce similar effects.
Ketamine is a nonselective NMDA receptor channel blocker, and targeting a specific NMDA receptor subtype or using a nonchannel blocker or a modulator of the NMDA receptor could result in antidepressant actions with fewer side effects. Preclinical and clinical studies demonstrate that selective NR2B receptor antagonists and nonselective, lowtrapping NMDA receptor antagonists, as well as allosteric modulators of NMDA channels (such as GLYX-13) produce antidepressant responses in rodent models and in humans, supporting this possibility 52, 55, 160, 168, 169 . Other potential targets that regulate glutamate transmission include antagonists of presynaptic metabotropic glutamate (mGlu) 2/3 inhibitory autoreceptors that increase glutamate release and postsynaptic AMPA receptorpotentiating agents that directly increase receptor function 170, 171 . There are also intracellular pathway molecules (such as glycogen synthase kinase (GSK) 3 and the MAP kinase phosphatase DUSP1 (also called MKP1)) that negatively regulate mTORC1 and related p e r s p e c t i v e signaling cascades that could be targeted 46, 172 . However, recent reports of negative phase 2 clinical trials for depression with some of these drugs targeting the NMDA and mGlu2/3 receptors raise concerns about the general efficacy of some of these targets and remind us of the difficulty in conducting clinical trials in this population. In addition to glutamatergic agents, it has been found that low doses of scopolamine produce rapid antidepressant actions in individuals with depression 153 . Scopolamine also acutely stimulates mTORC1 signaling, leading to increased synaptogenesis in the PFC 53 (Fig. 4) . Studies to identify the receptor subtype indicate that a selective muscarinic 1 antagonist produces antidepressant actions similar to those of scopolamine, using rodent models 173, 174 . Preclinical studies also report that other putative antidepressant agents increase, or are dependent on, mTORC1 signaling [175] [176] [177] [178] . Together, these studies provide additional evidence supporting the idea that the mTORC1-dependent translational cascade in dendrites and synapse formation may represent a common final pathway for a wide range of rapid-acting, efficacious antidepressants.
Summary and conclusions
Together, clinical and basic research studies demonstrate an emerging focus on the glutamate synapse as a major target for stress, depression and novel rapid-acting antidepressants. The atrophy of neurons and the loss of glutamatergic synaptic connections caused by stress are key contributors to the symptoms of depression. In addition to the HPA axis, synaptic number and function are altered by other factors (notably neurotrophic factors) that have been implicated in depression and other mood disorders, fluctuations of ovarian steroids, metabolic factors and inflammatory cytokines (Figs. 3 and 4) . Interactions between these factors can also lead to increased susceptibility to depression. Genetic studies have been hampered by the heterogeneity of depression, low heritability and the contribution of multiple, low-impact gene loci; progress will require consideration of these heterogeneous factors, as well as other environmental conditions. The discovery of a new class of antidepressant agents that produce rapid antidepressant effects has had a major impact on the field, not only by providing a sorely needed rapid and efficacious treatment but also a strategy to identify additional therapeutic-response targets. Notably, using preclinical models, these new agents rapidly increase synaptic connections and reverse the loss of synapses that are caused by stress, thereby directly targeting the pathophysiology underlying depression (Fig. 4) . These findings provide a roadmap for ongoing and future drug discovery efforts to identify agents that restore glutamate synaptic connectivity as novel, rapid and efficacious treatments with limited side effects. In addition, studies are underway to identify other therapeutic strategies that can naturally increase, strengthen and stabilize synapses in depression circuits, including adjunctive drug treatments and cognitive behavioral therapy. Together these findings provide enormous promise for a new generation of therapeutic strategies for pervasive and devastating mood disorders. 
